Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. (Q45093247)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21898376%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

title

Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21898376%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

main subject

phase II clinical trial

0 references

author

Michael P. Brown

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21898376%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Se-Hoon Lee

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21898376%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Sun Young Rha

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21898376%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Carlos H Barrios

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21898376%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

David Hernandez-Barajas

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21898376%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Luis Fein

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21898376%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Jin-Hwang Liu

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21898376%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Subramanian Hariharan

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21898376%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Bridget A Martell

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21898376%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Jinyu Yuan

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21898376%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Akintunde Bello

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21898376%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Zhixiao Wang

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21898376%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Rajiv Mundayat

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21898376%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

language of work or name

English

0 references

publication date

6 September 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21898376%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21898376%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

118

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21898376%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21898376%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

1252-1259

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21898376%20AND%20SRC:MED&resulttype=core&format=json

Sorafenib in advanced clear-cell renal-cell carcinoma

12 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26440

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26440

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26440

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26440

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26440

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26440

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26440

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26440

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26440

Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26440

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26440

Development and validation of a scale to measure disease-related symptoms of kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26440

Fatigue in cancer patients compared with fatigue in the general United States population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26440

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26440

Sunitinib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26440

Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26440

The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26440

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26440

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26440

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26440

Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26440

Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26440